Enanta Pharmaceuticals is in the healthcare sector and is in the biotechnology industry. The company CEO is Jay R. Luly. Enanta Pharmaceuticals Inc is a biotechnology company. It is engaged in the research and development of small molecule drugs for infectious diseases. The Group uses its chemistry-driven approach and drug discovery capabilities to develop its products.
Previous Intraday Trading Performance:
The ENTA stock showed a previous change of -7.43% with an open at 81.78 and a close of 76.02. It reached an intraday high of 82.00 and a low of 75.60.
The stock has a market cap of $1.5b with 19.4m shares outstanding, of which the float is 18.4m shares. Trading volume reached 349,445 shares compared to its average volume of 266,511 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.
Historical Trading Performance:
Over the last five trading days, Enanta Pharmaceuticals shares returned -10.06% and in the past 30 trading days it returned -1.45%. Over three months, it changed -16.65%. In one year it has changed 57.13% and within that year its 52-week high was 127.77 and its 52-week low was 47.01. ENTA stock is 61.71% above its 52 Week Low.
Our calculations show a 200 day moving average of 92.45 and a 50 day moving average of 79.46. Currently ENTA stock is trading -17.78% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.
The last annual fiscal EPS for the company was reported at 3.66 that ended on 30th of September 2018, which according to the previous close, that is a PE of 21.84. Based on 4 analyst estimates, the consensus EPS for the next quarter is 0.96. The TTM EPS is 4.22, which comes to a TTM PE of 18.01.
The following are the last four quarter reported earnings per share:
Indicators to Watch:
Based on the latest filings, there is 125.80% of institutional ownership. Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.
The current calculated beta is 0.95
Based on last reported financials, the company’s return on equity is 20.79%, return on assets is 19.51%, profit margin is 35.04%, price-to-sales is 7.72 and price-to-book is 3.75.
All scores are out of six:
1 :Valuation Score
4 :Past Performance Score
5 :Financial Strength Score
0 :Future Growth Score
0 :Dividend Score
2 :Overall Score